Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348

VIFOR PHARMA

(VIFN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
12/05/2019 12/06/2019 12/09/2019 12/10/2019 12/11/2019 Date
176.25(c) 176.35(c) 176.55(c) 175.5(c) 174.2 Last
113 677 100 722 119 688 137 345 24 037 Volume
+0.54% +0.06% +0.11% -0.59% -0.74% Change
More quotes
Financials (CHF)
Sales 2019 1 888 M
EBIT 2019 331 M
Net income 2019 157 M
Debt 2019 130 M
Yield 2019 1,14%
Sales 2020 2 105 M
EBIT 2020 492 M
Net income 2020 313 M
Finance 2020 106 M
Yield 2020 1,15%
P/E ratio 2019 71,1x
P/E ratio 2020 36,6x
EV / Sales2019 6,10x
EV / Sales2020 5,35x
Capitalization 11 380 M
More Financials
Company
Vifor Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency and nephrological and cardiovascular disorders. Vitor Pharma also markets a diversified portfolio of prescription drugs and OTC products. At the end of... 
Sector
Pharmaceuticals
Calendar
12/10Presentation
More about the company
Surperformance© ratings of Vifor Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on VIFOR PHARMA
11/27CHEMOCENTRYX : Vifor Pharma - VFMCRP and ChemoCentryx announce positive topline ..
AQ
11/26EUROPE : Positive trade sentiment nudges European stocks higher
RE
11/26VIFOR PHARMA : raises awareness on Iron Deficiency Day 2019 for people around th..
BU
11/18VIFOR PHARMA : Appoints Lee Heeson as President International and Member of the ..
BU
11/06CHEMOCENTRYX : Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoC..
AQ
11/06VIFOR PHARMA : and Evotec form joint venture for early development in nephrology
BU
11/04GLOBAL MARKETS LIVE : PSA, Fiat Chrysler, Fitbit, McDonald’s…
11/04VIFOR PHARMA : Enters Into Commercial Collaboration in the US with Janssen
BU
09/11VIFOR PHARMA : Appoints New Chief Medical Officer and Announces Changes to Execu..
BU
09/09VIFOR PHARMA : announces the initiation of S&P credit rating coverage with an in..
BU
08/08GLOBAL MARKETS LIVE : Uber, Broadcom, Carlsberg, Salesforce…
08/08VIFOR PHARMA GROUP : Reports Strong H1 2019 Results and Raises Full-year Guidanc..
BU
05/26VIFOR PHARMA : Pioneering Project for Pharmaceutics – Vifor Pharma and the..
BU
05/22VIFOR PHARMA : First patient treated in DIAMOND study to evaluate if Veltassa im..
AQ
05/21VIFOR PHARMA : First patient treated in DIAMOND study to evaluate if Veltassa® (..
BU
More news
News in other languages on VIFOR PHARMA
12/06Aktien Schweiz Schluss: Deutliche Gewinne dank starker US-Daten
12/05Aktien Schweiz: Erholung hält an - SMI baut Gewinne leicht aus
11/29Aktien Schweiz Schluss: Trotz erneuter Verluste insgesamt starke Woche
11/29Bourse Zurich: la prudence prédomine toujours en fin de matinée
11/29Aktien Schweiz: SMI gibt nach - Gewinnmitnahmen vor dem Wochenende
More news
Analyst Recommendations on VIFOR PHARMA
More recommendations
Sector news : Pharmaceuticals - NEC
12/10DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
12/10Amazon victim of unfair treatment by the White House?
12/10ALLERGAN : Form 8.3 -
DJ
12/10Sanofi shares rally on new margin goals, narrower drug focus
RE
12/10ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart VIFOR PHARMA
Duration : Period :
Vifor Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 169,58  CHF
Last Close Price 175,50  CHF
Spread / Highest target 11,1%
Spread / Average Target -3,37%
Spread / Lowest Target -31,6%
EPS Revisions
Managers
NameTitle
Gianni Zampieri Chief Executive Officer & Director
Stefan Schulze President & Chief Operating Officer
Etienne Jornod Executive Chairman
Colin Bond Chief Financial Officer
Michel Burnier Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA64.17%11 552
JOHNSON & JOHNSON8.87%368 436
ROCHE HOLDING AG25.45%262 617
MERCK AND COMPANY16.11%226 847
PFIZER-11.84%212 953
NOVARTIS22.87%209 790